null
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$0
-2.30
$29.9B
undefined
emptyResult
undefined
Recently from Cashu
BeiGene Ltd. Expands Oncology Portfolio with Exclusive Option on DualityBio’s B7H4 ADC
BeiGene Expands Oncology Portfolio with Exclusive Option on DualityBio’s B7H4 ADC In a significant development for the oncology landscape, BeiGene, Ltd. has exercised its exclusive option for Duality…
BeiGene Ltd Positioned for Growth Amid Biotech Sector Revival and M&A Activity
Biotech Sector Poised for Revival Amid M&A Anticipation The biotech industry shows signs of potential recovery in 2025, as analysts predict increased merger and acquisition (M&A) activity and new drug…
BeiGene Ltd Positioned for Growth Amid Biotech Sector Revival and Strategic Acquisitions
Biotech Sector Poised for Revival: A Focus on Innovation and Acquisition As the biotech sector anticipates a resurgence in 2025, companies like BeiGene Ltd are positioned to capitalize on emerging opp…
BeiGene Ltd. Gains FDA Approval for TEVIMBRA® in Advanced Gastric Cancer Treatment
BeiGene Secures FDA Approval for TEVIMBRA® in Gastric Cancer Treatment BeiGene, Ltd., soon to be rebranded as BeOne Medicines Ltd., achieves a notable milestone in oncology with the U.S. Food and Drug…